Treatment With Rosuvastatin for Severe Dyslipidemia in Patients With Schizophrenia and Schizoaffective Disorder
J Clin Psychiatry 2006;67(12):1889-1896
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: Mortality rates in patients with schizophrenia
are double compared to those in the general population, with cardiovascular
disease causing 50% of the excess. Lowering low-density lipoprotein (LDL)
cholesterol is recognized as a primary target for the prevention of
cardiovascular mortality according to the National Cholesterol Education
Program-Adult Treatment Panel III. Use of lipid-lowering drugs such as statins
is recommended when lifestyle changes are not sufficient to reach the LDL goal.
The efficacy and safety of rosuvastatin treatment were evaluated in
Method: 100 schizophrenic patients with severe
dyslipidemia were identified. All were treated with antipsychotics. Fifty-two
patients were treated with rosuvastatin and compared with 48 who did not receive
statin treatment. All patients were screened for cardiovascular risk factors and
examined at baseline. The effects of lipid-lowering medication on lipid profile,
glucose homeostasis, and components of metabolic syndrome were evaluated at
3-month follow-up. The study began in 2003, and all data available until
December 2005 are reported.
Results: After 3 months of statin therapy, a significant
decrease in triglycerides, total cholesterol, LDL cholesterol, and
non-high-density lipoprotein (non-HDL) cholesterol and in associated ratios (LDL/HDL,
total cholesterol/HDL) was observed. The difference was highly significant
compared to patients not receiving statin treatment. No significant changes
occurred in HDL cholesterol, body mass index and waist circumference, or glucose
homeostasis. The only component of metabolic syndrome affected by statin therapy
was the serum triglyceride level.
Conclusion: Rosuvastatin proved effective in the
management of dyslipidemia in patients with schizophrenia treated with
antipsychotics. More complex treatment may be required for associated metabolic